双滤过血浆置换联合利妥昔单抗用于单倍体造血干细胞移植供者特异性抗体脱敏
该嵌套病例对照研究纳入33例供者特异性抗体(DSA)阳性并接受双滤过血浆置换(DFPP)联合利妥昔单抗脱敏的单倍体造血干细胞移植患者,随机匹配99例DSA阴性对照。DFPP后DSA平均荧光强度中位数由7505.88±4424.38降至2013.29±4067.22(p<0.001),DSA组全部实现造血重建,3年非复发死亡率和总生存率与阴性对照相当。
要点
- DFPP联合利妥昔单抗脱敏后DSA平均荧光强度中位数由7505.88±4424.38降至2013.29±4067.22(p<0.001)。
- DSA组全部患者实现造血重建,中性粒细胞和血小板植入中位时间分别为13(10-21)天和13(10-29)天。
- DSA组3年非复发死亡率和总生存率分别为6.39%和72.0%,与DSA阴性对照相当。
核心结论
- DFPP联合利妥昔单抗可有效用于脱敏,并克服DSA在单倍体造血干细胞移植中的负面影响。
研究设计与样本
- 嵌套病例对照研究:33例DSA阳性患者接受DFPP联合利妥昔单抗脱敏方案,随机匹配99例DSA阴性患者作为对照。
主要发现
- DFPP治疗前后DSA平均荧光强度中位数分别为7505.88±4424.38和2013.29±4067.22(p<0.001)。
- DSA组全部患者实现造血重建,中性粒细胞和血小板植入中位时间分别为13(10-21)天和13(10-29)天。
- DSA组与对照组II-IV级急性移植物抗宿主病累积发生率分别为41.4%和28.1%,3年中重度慢性移植物抗宿主病累积发生率分别为16.8%和7.2%,均无统计学显著性差异。
- DSA组3年非复发死亡率为6.39%,总生存率为72.0%,与DSA阴性对照相当。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Donor-specific anti-HLA antibodies (DSA) are a major cause of engraftment failure in patients receiving haploidentical haematopoietic stem cell transplantation (Haplo-HSCT). Double filtration plasmapheresis (DFPP) avoids the unnecessary loss of plasma proteins and increases the efficiency of purification. To investigate the effectiveness of the desensitization protocol including DFPP and rituximab, we conducted a nested case-control study. Thirty-three patients who had positive DSA were desensitized by the protocol and 99 patients with negative DSA were randomly matched as control. The median DSA mean fluorescence intensity values before and after DFPP treatment were 7505.88 ± 4424.38 versus 2013.29 ± 4067.22 (p < 0.001). All patients in DSA group achieved haematopoietic reconstitution and the median neutrophils and platelets engraftment times were 13 (10-21) and 13 (10-29) days respectively. Although the cumulative incidence of II-IV aGVHD (41.4% vs. 28.1%) and 3-year moderate to severe cGVHD (16.8% vs. 7.2%) were higher in DSA cohort than in the control, no statistical significance was observed. The 3-year non-relapse mortality and the overall survival were 6.39% and 72.0%, respectively, in the DSA cohort, which were comparable to the negative control. In conclusion, DFPP and rituximab could be effectively used for desensitization and overcome the negative effects of DSA in Haplo-HSCT.
引用
- Liu L, Ji X, Zhu P, et al. Double filtration plasmapheresis combined with rituximab for donor-specific antibody desensitization in haploidentical haematopoietic stem cell transplantation. Br J Haematol. 2023. PMID: 37621146. doi:10.1111/bjh.19046
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。